3D Coumarin systems based on [2.2]paracyclophane: synthesis, spectroscopic characterization and chiroptical properties

Marie-Léonie Delcourt,^a Corentin Reynaud, ^a Serge Turcaud, ^a Ludovic Favereau,^b Jeanne Crassous,^b Laurent Micouin, ^{a,} and Erica Benedetti^{a,*}*

^a UMR 8601 CNRS, Université Paris Descartes, Sorbonne Paris Cité, UFR Biomédicale, 45 rue des Saints Pères, 75006 Paris (France).

^b Univ Rennes, Institut des Sciences Chimiques de Rennes, UMR 6226 CNRS, Campus de Beaulieu, 35042 Rennes Cedex (France).

e-mail: erica.benedetti@parisdescartes.fr; laurent.micouin@parisdescartes.fr; Fax: + (33) 1 42 86 43 84


Supporting Information

Table of Contents

Synthesis of model compounds 7a,b	S 3
HPLC analyses	S5
UV-Vis and Fluorescence spectroscopy	S9
Circular dichroism and circularly polarized luminescence	S27
¹ H NMR and ¹³ C NMR spectra	S29


Synthesis of model compounds 7a,b

Synthesis of 2,5-dimethylphenyl 3-phenylpropiolate (Compound S1)




Phenylpropiolic acid (125 mg, 0.859 mmol, 1.05 eq.), DMAP (15 mg, 0.123 mmol, 0.15 eq.) and 2,5-dimethylphenol (100 mg, 0.103 mL, 0.819 mmol, 1 eq.) were dissolved in dry DCM (15 mL) under an Argon atmosphere. DCC (1 M, 0.982 mL, 0.982 mmol, 1.2 eq.) was added turning the reaction mixture yellow and cloudy. The reaction was stirred at rt for 1 h, followed by filtration through a plug of silica gel with DCM washings. The crude material was then concentrated under reduced pressure and purified by silica gel column chromatography (eluent = DCM/Cy 4:6) to yield compound **S1** (181 mg, 0.723 mmol, 88 %) as a white solid. ¹H **NMR** (500 MHz, CDCl₃) δ 7.67 – 7.61 (m, 2H), 7.52 – 7.45 (m, 1H), 7.41 (t, *J* = 7.5 Hz, 2H), 7.15 (d, *J* = 7.7 Hz, 1H), 7.01 (d, *J* = 7.7 Hz, 1H), 6.93 (s, 1H), 2.35 (s, 3H), 2.23 (s, 3H) ppm. ¹³C **NMR** (125 MHz, CDCl₃) δ 152.3 (C), 148.5 (C), 137.1 (C), 133.2 (2CH), 131.0 (CH), 130.9 (CH), 128.6 (2CH), 127.3 (CH), 126.8 (C), 122.2 (CH), 119.3 (C), 88.4 (C), 80.2 (C), 20.8 (CH₃), 15.7 (CH₃) ppm. IR (neat): 2216, 1724, 1508, 1490, 1444, 1282, 1240, 1180, 1000, 912, 757 cm⁻¹. HRMS (ESI): *m/z* [M+H]⁺ calcd for C₁₇H₁₅O₂: 251.1067; found: 251.1066.

Synthesis of 2,5-dimethylphenyl but-2-ynoate (Compound S2)




2-Butynoic acid (72.3 mg, 0.859 mmol, 1.05 eq.), DMAP (15 mg, 0.123 mmol, 0.15 eq.) and 2,5-dimethylphenol (100 mg, 0.819 mmol, 1 eq.) were dissolved in dry DCM (15 mL) under an Argon atmosphere. DCC (1 M in DCM, 0.982 mL, 0.982 mmol, 1.2 eq.) was added turning the mixture cloudy. The reaction was stirred at rt for 1 h, followed by filtration through a plug of silica gel with DCM washings. The crude material was concentrated under reduced pressure and purified by silica gel column chromatography (eluent = DCM/Cy 3:7) to afford compound **S2** (123 mg, 0.653 mmol, 80 %) as a colorless oil. ¹H NMR (500 MHz, CDCl₃) δ 7.11 (d, *J* = 7.7 Hz, 1H), 6.97 (d, *J* = 7.7 Hz, 1H), 6.86 (s, 1H), 2.32 (s, 3H), 2.16 (s, 3H), 2.07 (s, 3H) ppm. ¹³C NMR (125 MHz, CDCl₃) δ 151.9 (C), 148.4 (C), 137.0 (C), 130.9 (CH), 127.2 (CH), 126.7 (C), 122.2 (CH), 87.7 (C), 72.1 (C), 20.8 (CH₃), 15.7 (CH₃), 3.9 (CH₃) ppm. IR (neat): 2233, 1725, 1508, 1251, 1229, 1203, 1106, 1042, 886, 810, 741 cm⁻¹. HRMS (ESI): *m/z* [M+H]⁺ calcd for C₁₂H₁₃O₂: 189.0910; found: 189.0912.

Synthesis of 5,8-dimethyl-4-phenyl-2H-chromen-2-one (Compound 7a)



A G10 Anton Paar microwave vial was charges with AuCl₃ (4.93 mg, 0.0162 mmol, 0.08 eq.), and AgSbF₆ (11.5 mg, 0.0336 mmol, 0.17 eq.). The tube was sealed, then evacuated and refilled with argon three times. DCE (2 mL) was then added and the resulting mixture was stirred at rt for 5 min. Compound **S1** (50 mg, 0.2 mmol, 1 eq.) in DCE (2 mL) was finally added. The solution was irradiated in a microwave reactor at 80 °C for 7 min. At the end of the reaction, TLC showed no traces of starting material. The crude product was purified over silica gel column chromatography using EtOAc/Cy 1:9 as the eluent. Compound **7a** (26 mg, 0.104 mmol, 52 %) was isolated as an amorphous white solid. ¹**H NMR** (500 MHz, CDCl₃) δ 7.43 (dd, *J* = 4.2, 2.2 Hz, 3H), 7.30 – 7.21 (m, 3H), 6.89 (d, *J* = 7.6 Hz, 1H), 6.23 (s, 1H), 2.45 (s, 3H), 1.77 (s, 3H) ppm. ¹³**C NMR** (125 MHz, CDCl₃) δ 160.3 (C), 157.0 (C), 153.2 (C), 139.7 (C), 134.8 (C), 132.6 (CH), 128.7 (CH), 128.6 (2CH), 127.6 (CH), 127.4 (2CH), 124.5 (C), 117.6 (C), 117.0 (CH), 23.3 (CH₃), 15.9 (CH₃) ppm. IR (neat): 1728, 1583, 1445, 1407, 1346, 1268, 1184, 1059, 903, 866, 817, 781, 740 cm⁻¹. HRMS (ESI): *m*/*z* [M+Na]⁺ calcd for C₁₇H₁₄O₂Na: 273.0886; found: 273.0885.

Synthesis of 4,5,8-trimethyl-2H-chromen-2-one (Compound 7b)



A G10 Anton Paar microwave vial was charges with AuCl₃ (6.55 mg, 0.0216 mmol, 0.08 eq.), and AgSbF₆ (15.4 mg, 0.0447 mmol, 0.17 eq.). The tube was sealed, then evacuated and refilled with argon three times. DCE (1 mL) was then added and the resulting mixture was stirred at rt for 5 min. Compound **S2** (50 mg, 0.266 mmol, 1 eq.) in DCE (2 mL) was finally added. The solution was irradiated in a microwave reactor at 80 °C for 7 min. At the end of the reaction, TLC showed no traces of starting material. The crude product was purified over silica gel column chromatography using EtOAc/Cy 3:7 as the eluent. Compound **7b** (34 mg, 0.181 mmol, 68 %) was isolated as an amorphous white solid. ¹H NMR (500 MHz, CDCl₃) δ 7.21 (d, *J* = 7.6 Hz, 1H), 6.94 (d, *J* = 7.6 Hz, 1H), 6.25 – 6.16 (m, 1H), 2.67 (s, 3H), 2.60 (d, *J* = 1.1 Hz, 3H), 2.39 (s, 3H) ppm.¹³C NMR (125 MHz, CDCl₃) δ 160.4 (C), 154.5 (C), 153.2 (C), 134.1 (C), 132.2 (CH), 127.6 (CH), 124.8 (C), 118.9 (C), 116.2 (CH), 25.2 (CH₃), 24.3 (CH₃), 16.0 (CH₃) ppm. IR (neat): 1703, 1585, 1411, 1206, 1136, 1064, 920, 819 cm⁻¹. HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₁₂H₁₃O₂: 189.0910; found: 189.0909.


HPLC analyses

(Sp)- and (Rp)-4-hydroxy-[2.2]paracyclophane (compound 3a)


ОН

HPLC conditions: Column = Chiralcel OD (250 x 4,6 mm); eluent = *n*-heptane/*i*-PrOH (9:1); T = 25 °C; flow = 1 mL/min; λ = 250 nm.


HPLC analysis of racemic (\pm)-**3a** (tr _{*Sp*} = 14.2 min; tr _{*Rp*} = 16.6 min)



HPLC analysis of (Sp)-**3a** (tr _{Sp} = 14.2 min)



HPLC analysis of (Rp)-**3a** (tr _{*Sp*} = 16.4 min)




(*Sp*)- and (*Rp*)-Tricyclo[8.2.2.2⁴{4,7}]hexadeca-1(12),4(16),5,7(15),10,13-hexaen-5-yl but-2-ynoate (compound 2b)




HPLC Conditions: Column = Chiralcel AD (250 x 4,6 mm); eluent = *n*-heptane/*i*-PrOH (9:1); T = 25 °C; flow = 1 mL/min; λ = 254 nm.


HPLC analysis of racemic (±)-2b (tr $_{Rp}$ = 7.7 min; tr $_{Sp}$ = 10.1 min)




HPLC analysis of (Sp)-2b (tr $_{Sp}$ = 10.1 min)




HPLC analysis of (Rp)-2b (tr $_{Rp}$ = 7.6 min; tr $_{Sp}$ = 10.0 min)



(*Sp*)- and (*Rp*)-15-:ethyl-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17,19-heptaen-13-one (<u>Compound 1b</u>)




HPLC conditions: Column = Chiralcel OD (250 x 4,6 mm); eluent = *n*-heptane/*i*-PrOH (9:1); T = 25 °C; flow = 1 mL/min; λ = 250 nm.




HPLC analysis of racemic (\pm)-1b (tR _{Sp} = 15.4 min; tR _{Rp} = 17.6 min)

HPLC analysis of (Sp)-1b (tR $_{Sp} = 15.4 \text{ min}$)




HPLC analysis of (Rp)-1b (tR $_{Rp}$ = 17.2 min)




~	~
ς	2
	0

UV-Vis and Fluorescence spectroscopy

15-Phenyl-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17,19-heptaen-13-one (**Compound** (±)-1a)







Absorbance max: <u>285 nm</u>, <u>300 nm</u>, <u>330 nm</u> (1•10⁻⁴ M solution in DCE); Emission max: <u>460 nm</u> (1•10⁻⁴ M solution in DCE, $\lambda_{ex} = 340$ nm, $\varepsilon_{340nm} = 5240$ cm⁻¹·M⁻¹ at 10 °C). A 1•10⁻⁴ M solution of (±)-**1a** in DCE was used to perform the photodegradation study. The sample was continuously irradiated for 110 min at 20 °C ($\lambda_{ex} = 340$ nm) and maximum emission intensity changes

 $(\lambda_{max} = 460 \text{ nm})$ were measured at 5-minute time intervals. QY n.d. (<0.1%).

15-Methyl-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17,19-heptaen-13-one (**Compound** (±)-**1b**)






Absorbance max: <u>301 nm and 319 nm (1·10⁻⁴ M solution in DCE)</u>; Emission max: <u>435 nm</u> (1·10⁻⁴ M solution in DCE, $\lambda_{ex} = 340$ nm, $\varepsilon_{340nm} = 3370$ cm⁻¹·M⁻¹ at 10 °C). A 1·10⁻⁴ M solution of (±)-**1b** in DCE was used to perform the photodegradation study. The sample was continuously irradiated for 110

min at 20 °C (λ_{ex} = 340 nm) and maximum emission intensity changes (λ_{max} = 435 nm) were measured at 5-minute time intervals. QY in DCE at 20 °C = <u>0.01.</u>¹


¹ Relative quantum yield (QY) was calculated using anthracene in ethanol as fluorescence standard (QY = 0.27). The excitation wavelength was fixed at 340 nm for both the sample and the standard.


15-(Propan-2-yl)-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17,19heptaen-13-one (**Compound** (±)-1c)



Absorbance max: <u>300 nm and 320 nm (1</u>•10⁻⁴ M solution in DCE); Emission max: <u>432 nm</u> (1•10⁻⁴ M solution in DCE, $\lambda_{ex} = 340$ nm, $\varepsilon_{340nm} = 3150$ cm⁻¹·M⁻¹ at 10 °C). A 1•10⁻⁴ M solution of (±)-1c in DCE was used to perform the photodegradation study. The sample was continuously irradiated for 110 min at 20 °C ($\lambda_{ex} = 340$ nm) and maximum emission intensity changes ($\lambda_{max} = 432$ nm) were measured at 5-minute time intervals. QY n.d. (<0.1%).

12-Oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17,19-heptaen-13-one (Compound (±)-1d)






Absorbance max: <u>304 nm and 320 nm (1.10-4 M solution in DCE)</u>; Emission max: <u>445 nm (1.10-4 M solution in DCE, $\lambda_{ex} = 340$ nm, $\varepsilon_{340nm} = 3160$ cm^{-1.}M⁻¹ at 10 °C). A 1.10-4 M solution of (±)-1d in DCE was used to perform the photodegradation study. The sample was continuously irradiated for 120</u>

min at 20 °C (λ_{ex} = 340 nm) and maximum emission intensity changes (λ_{max} = 445 nm) were measured at 5-minute time intervals. QY n.d. (<0.1%).

5-Bromo-15-phenyl-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17,19heptaen-13-one (**Compound** (±)-**1**e)





Br C C C C

Absorbance max: <u>307 nm and 325 nm (1</u>•10⁻⁴ M solution in DCE); Emission max: <u>450 nm</u> (1•10⁻⁴ M solution in DCE, $\lambda_{ex} = 320$ nm, $\varepsilon_{320nm} = 6900$ cm⁻¹·M⁻¹ at 10 °C). A 1•10⁻⁴ M solution of (±)-1e in DCE was used to perform the photodegradation study. The sample was continuously irradiated for 105 min at 20 °C ($\lambda_{ex} = 320$ nm)

and maximum emission intensity changes ($\lambda_{max} = 450 \text{ nm}$) were measured at 5-minute time intervals. QY n.d. (<0.1%).

5-Bromo-15-methyl-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17,19heptaen-13-one (**Compound** (±)-**1**f)






Absorbance max: <u>306 nm and 320 nm (1</u>•10⁻⁴ M solution in DCE); Emission max: <u>425 nm</u> (1•10⁻⁴ M solution in DCE, $\lambda_{ex} = 340$ nm, $\varepsilon_{340nm} = 3230$ cm⁻¹·M⁻¹ at 10 °C). A 1•10⁻⁴ M solution of (±)-**1f** in DCE was used to perform the photodegradation study. The sample was


continuously irradiated for 110 min at 20 °C ($\lambda_{ex} = 340$ nm) and maximum emission intensity changes ($\lambda_{max} = 425$ nm) were measured at 5-minute time intervals. QY n.d. (<0.1%).

15-(4-Methylphenyl)-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17,19-heptaen-13-one (Compound (±)-*1g*)



Absorbance max: <u>300 nm</u>, <u>330 nm</u> (1•10⁻⁴ M solution in DCE); Emission max: <u>455 nm</u> (1•10⁻⁴ M solution in DCE, $\lambda_{ex} = 340$ nm, $\varepsilon_{340nm} = 6220$ cm⁻¹·M⁻¹ at 10 °C). A 1•10⁻⁴ M solution of (±)-1g in DCE was used to perform the photodegradation study. The sample was continuously irradiated for 110 min at 20 °C ($\lambda_{ex} = 340$ nm) and maximum emission intensity changes (λ_{max} = 455 nm) were measured at 5-minute time intervals. QY n.d. (<0.1%).

 $15-(4-Methoxyphenyl)-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17-,19-heptaen-13-one (Compound (±)-1h)$





Ome O

Absorbance max: $\underline{315} \text{ nm} (1 \cdot 10^{-4} \text{ M solution in DCE})$; Emission max: $\underline{455} \text{ nm} (1 \cdot 10^{-4} \text{ M solution in DCE}, \lambda_{ex} = 330 \text{ nm}, \varepsilon_{330\text{nm}} = 7400 \text{ cm}^{-1} \cdot \text{M}^{-1} \text{ at } 10 \text{ °C})$. A $1 \cdot 10^{-4} \text{ M}$ solution of (±)-**1h** in DCE was used to perform the photodegradation study. The sample was continuously irradiated for 110 min at 20 °C ($\lambda_{ex} = 330$ nm) and maximum emission intensity changes ($\lambda_{max} = 455$ nm) were measured

at 5-minute time intervals. QY n.d. (<0.1%).


15-(4-Chlorophenyl)-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17,19heptaen-13-one (**Compound** (±)-1*i*)





Absorbance max: <u>288 nm</u>, <u>310 nm</u>, <u>335 nm</u> (1•10⁻⁴ M solution in DCE); Emission max: <u>465 nm</u> (1•10⁻⁴ M solution in DCE, $\lambda_{ex} = 340$ nm, $\varepsilon_{340nm} = 6310$ cm⁻¹·M⁻¹ at 10 °C). A 1•10⁻⁴ M solution of (±)-**1i** in DCE was used to perform the photodegradation study. The sample was continuously irradiated for 110 min at 20 °C ($\lambda_{ex} = 340$ nm) and maximum emission intensity changes ($\lambda_{max} = 465$ nm) were measured at 5-minute time intervals. QY n.d. (<0.1%).

4-{13-Oxo-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17,19-heptaen-15-yl}phenyl trifluoromethanesulfonate (**Compound** (±)-**1**j)






όтf

Absorbance max: <u>280 nm and 330 nm (1</u>•10⁻⁴ M solution in DCE); Emission max: <u>470 nm</u> (1•10⁻⁴ M solution in DCE, $\lambda_{ex} = 340$ nm, $\varepsilon_{340nm} = 5460$ cm⁻¹·M⁻¹ at 10 °C). A 1•10⁻⁴ M solution of (±)-**1j** in DCE was used to perform the photodegradation study. The sample was continuously irradiated for 100 min at 20 °C ($\lambda_{ex} = 340$ nm) and maximum emission intensity changes ($\lambda_{max} = 470$

nm) were measured at 5-minute time intervals. QY n.d. (<0.1%).


15-[4-(Trifluoromethyl)phenyl]-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17,19-heptaen-13-one (Compound (±)-1k)




Absorbance max: <u>270 nm and 335 nm (1.10-4 M solution in DCE)</u>; Emission max: <u>475 nm</u> (1.10-4 M solution in DCE, $\lambda_{ex} = 340$ nm, $\varepsilon_{340nm} = 5500$ cm⁻¹·M⁻¹ at 10 °C). A 1.10-4 M solution of (±)-1k in DCE was used to perform the photodegradation study. The sample was continuously irradiated for 110 min at 20 °C ($\lambda_{ex} = 340$ nm) and maximum emission intensity changes (λ_{max}

= 475 nm) were measured at 5-minute time intervals. QY n.d. (<0.1%).

2,2-Dimethyl-N-{13-oxo-15-phenyl-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa1(16), 4(20),5,7(19),10,14,17-heptaen-5-yl}propanamide (*Compound* (±)-11)






and maximum emission intensity changes ($\lambda_{max} = 483 \text{ nm}$) were measured at 5-minute time intervals. QY n.d. (<0.1%).

BocHN


20-Amino-15-phenyl-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17,19heptaen-13-one (Compound (±)-1m)



Absorbance max: <u>330 nm (1•10⁻⁴ M solution in DCE)</u>; Emission max: <u>575 nm (1•10⁻⁴ M solution in DCE, $\lambda_{ex} = 365$ nm, $\varepsilon_{365nm} = 2900$ cm⁻¹·M⁻¹ at 10 °C). A 1•10⁻⁵ M solution of (±)-**1m** in DCE was used to perform the photodegradation study. The sample was continuously irradiated for 110 min at 20 °C ($\lambda_{ex} = 365$ nm) and maximum emission intensity changes</u>

 $(\lambda_{\text{max}} = 575 \text{ nm})$ were measured at 5-minute time intervals. QY n.d. (<0.1%).

tert-Butyl N-(4-{13-oxo-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(17),4,6,10(18),11 (16),14,19-heptaen-15-yl}phenyl)carbamate (**Compound** (±)-**1***n*)




Absorban <u>nm</u> (1•10 °C). A photodeg min at 20

Absorbance max: <u>317 nm (1</u>•10⁻⁴ M solution in DCE); Emission max: <u>450</u> <u>nm (1</u>•10⁻⁴ M solution in DCE, $\lambda_{ex} = 310$ nm, $\varepsilon_{310nm} = 7800$ cm⁻¹·M⁻¹ at 10 °C). A 1•10⁻⁵ M solution of (±)-1n in DCE was used to perform the photodegradation study. The sample was continuously irradiated for 105 c min at 20 °C ($\lambda_{ex} = 315$ nm) and maximum emission intensity changes (λ_{max}

= 450 nm) were measured at 5-minute time intervals. QY n.d. (<0.1%).


15-(4-Aminophenyl)-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(17),4,6,10(18),11 (16),14,19-heptaen-13-one (**Compound** (±)-**1**0)



Absorbance max: 300 nm and 330 nm (1•10 °M solution in DCE); Emission max: 470 nm (1•10 °M solution in DCE), $\lambda_{ex} = 360 \text{ nm}$, $\varepsilon_{360nm} = 9500 \text{ cm}^{-1}$. M⁻¹ at 10 °C). A 1•10 °F M solution of (±)-10 in DCE was used to perform the photodegradation study. The sample was continuously irradiated for 100 min at 20 °C ($\lambda_{ex} = 360 \text{ nm}$) and maximum emission intensity changes (λ_{max} = 470 nm) were measured at 5-minute time intervals. QY in DCM at 20 °C = 0.05.²


² Relative quantum yield (QY) was calculated using anthracene in ethanol as fluorescence standard (QY = 0.27). The excitation wavelength was fixed at 340 nm for both the sample and the standard.

4-Amino[2.2]paracyclophane (Compound (±)-6)




Absorbance max: $\underline{274}$, $\underline{324}$ nm (1•10⁻⁴ M solution in DCM); Emission max: $\underline{386}$ nm (1•10⁻⁴ M solution in DCM, $\lambda_{ex} = 300$ nm). A 1•10⁻⁴ M solution of (±)-6 in DCM was used to perform the photodegradation study. The sample was continuously irradiated for 90 min at 20 °C ($\lambda_{ex} = 300$ nm) and maximum emission intensity changes ($\lambda_{max} = 386$ nm) were measured at 5-minute time intervals. QY n.d. (<0.1%).

5,8-Dimethyl-4-phenyl-2H-chromen-2-one (Compound 7a)



Absorbance max: <u>294, 310, 330, 350 nm (1.10-4 M solution in DCE)</u>; Emission max: <u>418 nm (1.10-4 M solution in DCE, $\lambda_{ex} = 340$ nm). A 1.10-4 M solution of **7a** in DCE was used to perform the photodegradation study. The sample was continuously irradiated for 95 min at 20 °C ($\lambda_{ex} = 340$ nm) and maximum emission intensity changes ($\lambda_{max} = 415$ nm) were measured at 5-minute time intervals. QY n.d. (<0.1%).</u>

4,5,8-Trimethyl-2H-chromen-2-one (Compound 7b)



Absorbance max: <u>286, 299, 330 nm (1</u>•10⁻⁴ M solution in DCE); Emission max: <u>413 nm (1</u>•10⁻⁴ M solution in DCE, $\lambda_{ex} = 310$ nm). A 1•10⁻⁴ M solution of **7b** in DCE was used to perform the photodegradation study. The sample was continuously irradiated for 90 min at 20 °C ($\lambda_{ex} = 310$ nm) and maximum emission intensity changes ($\lambda_{max} = 400$ nm) were measured at 5-minute time intervals. QY n.d. (<0.1%).

Circular dichroism and circularly polarized luminescence

The circular dichroism measurements for compounds (S_p) - and (R_p) -1b were performed in dichloromethane. The concentration of all the samples was ~10⁻⁵ M. Absorption dissymmetry factors were obtained using the following formula:

$$g_{abs} = \left| 2 \left[\varepsilon_{L} \left(\lambda \right) - \varepsilon_{R} \left(\lambda \right) \right] / \left[\varepsilon_{L} \left(\lambda \right) + \varepsilon_{R} \left(\lambda \right) \right] \right|$$

where ε_L and ε_R denote the molar extinction coefficients for left and right circularly polarized light, respectively.




Figure S1. Absorption dissymmetry factors of compounds (S_p) -1b and (R_p) -1b

The circularly polarized luminescence (CPL) measurements for compounds (S_p)- and (R_p)-1b were performed using a home-built CPL spectrofluoropolarimeter. The samples were excited using a 90° geometry with a Xenon ozone-free lamp 150 W LS. The following parameters were used: emission slit width ≈ 2 mm, integration time = 4 sec, scan speed = 50 nm/min, accumulations = 5. The concentration of all the samples was ~ 10⁻⁵ M in DCM. Excitation of the samples were performed at 330 nm.

Luminescence dissymmetry factors were obtained using the following formula:

$$g_{\text{lum}} = \left| 2 \left[I_{\text{L}} \left(\lambda \right) - I_{\text{R}} \left(\lambda \right) \right] / \left[I_{\text{L}} \left(\lambda \right) + I_{\text{R}} \left(\lambda \right) \right] \right|$$

were I_L and I_R are the photoluminescence intensities of left and right circularly polarized luminescence.






Figure S2. Luminescence dissymmetry factors of compounds (S_p) -1b and (R_p) -1b

¹H NMR and ¹³C NMR spectra

4-hydroxy[2.2]paracyclophane (Compound (±)-3a)




4-hydroxy-16-bromo-[2.2]paracyclophane (Compound (±)-3b)




S30


Tricyclo[8.2.2.2^{4,7}]*hexadeca-1(12)*,4,6,10,13,15-*hexaen-5-yl* 3-*phenylprop-2-ynoate* (*Compound* (±)-2*a*)



Tricyclo[8.2.2.2^{4,7}]*hexadeca*-1(12),4(16),5,7(15),10,13-*hexaen*-5-yl *but*-2-ynoate (*Compound* (±)-2*b*)




Tricyclo[8.2.2.2^{4,7}]hexadeca-1(12),4,6,10,13,15-hexaen-5-yl 4-methylpent-2-ynoate (Compound (\pm) -2c)




Tricyclo[8.2.2.2^{4,7}]*hexadeca*-1(12),4(16),5,7(15),10,13-*hexaen*-5-yl prop-2-ynoate (*Compound* (±)-2*d*)


m 8 V V O O V O 8 V O 4 4 O 8 M U 8 V U O 6 M O M O M O M O V O V O V O 0 V U V O 0 V O	
080000400000000000000000000000000000000	
い 4 % % ろ 4 ~ % 0 ~ 0 ~ 0 ~ 0 ~ 0 ~ 0 ~ 0 ~ 0 ~ 0 ~	
000000000000000000000000000000000000000	ファフ
· · · · · · · · · · · · · · · · · · ·	a a a




14-Bromotricyclo[8.2.2.2^{4,7}]hexadeca-1(12),4,6,10,13,15-hexaen-5-yl 3-phenylprop-2ynoate (**Compound** (±)-2e)




14-Bromotricyclo[8.2.2.2^{4,7}]hexadeca-1(12),4,6,10,13,15-hexaen-5-yl but-2-ynoate (Compound (±)-2f)




 $Tricyclo[8.2.2.2^{4,7}]hexadeca-1(12), 4, 6, 10, 13, 15-hexaen-5-yl 3-(4-methylphenyl)prop-2-ynoate (Compound (±)-2g)$




Tricyclo[8.2.2.2^{4,7}]*hexadeca*-1(12),4,6,10,13,15-*hexaen*-5-yl 3-(4-*methoxyphenyl*)*prop*-2ynoate (*Compound* (±)-2*h*)




Tricyclo[8.2.2.2^{4,7}]*hexadeca*-1(12),4,6,10,13,15*-hexaen*-5*-yl* 3-(4-chlorophenyl)*prop*-2*ynoate* (*Compound* (±)-2*i*)




 $Tricyclo[8.2.2.2^{4,7}]hexadeca-1(12),4(16),5,7(15),10,13-hexaen-5-yl 3-{4-[(trifluoro-methyl)sulfonyloxy]phenyl}prop-2-ynoate (Compound (±)-2l)$




 $Tricyclo[8.2.2.2^{4,7}]hexadeca-1(12), 4, 6, 10, 13, 15-hexaen-5-yl 3-[4-(trifluoromethyl)-phenyl]prop-2-ynoate (Compound (±)-2k)$







2,5-Dimethylphenyl but-2-ynoate (Compound S2)




15-Phenyl-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17,19-heptaen-13-one (**Compound** (±)-1a)




15-Methyl-12-oxatetracyclo[8.6.2.2⁴,7}.0^{11,16}]icosa-1(16),4,6,10,14,17,19-heptaen-13-one (**Compound** (±)-**1**b)




15-(Propan-2-yl)-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17,19heptaen-13-one (**Compound** (±)-1c)




12-Oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17,19-heptaen-13-one (Compound (±)-1d)




5-Bromo-15-phenyl-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17,19-heptaen-13-one (**Compound** (\pm)-**1***e*)




5-Bromo-15-methyl-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17,19heptaen-13-one (**Compound** (±)-**1**f)




15-(4-Methylphenyl)-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17,19heptaen-13-one (**Compound** (±)-**1**g)




15-(4-Methoxyphenyl)-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17, 19-heptaen-13-one (**Compound** (±)-**1**h)




15-(4-Chlorophenyl)-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17,19heptaen-13-one (**Compound** (±)-**1**i)




 $4-\{13-Oxo-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17,19-heptaen-15-yl\}phenyl trifluoromethanesulfonate ($ **Compound**(±)-**1***j*)




15-[4-(Trifluoromethyl)phenyl]-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17,19-heptaen-13-one (**Compound** (±)-**1**k)




2,2-Dimethyl-N-{13-oxo-15-phenyl-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4(20),5,7(19),10,14,17-heptaen-5-yl}propanamide (**Compound** (±)-**1**l)



20-Amino-15-phenyl-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa-1(16),4,6,10,14,17,19heptaen-13-one (**Compound** (±)-**1**m)



tert-Butyl N-(4-{13-oxo-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa1(17),4,6,10(18), 11(16),14,19-heptaen-15-yl}phenyl)carbamate (Compound (±)-1*n*)



15-(4-Aminophenyl)-12-oxatetracyclo[8.6.2.2^{4,7}.0^{11,16}]icosa1(17),4,6,10(18),11 (16),14,19-heptaen-13-one (**Compound** (±)-10)

